NCT01064037 - A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

March 31, 2011

Conditions

Heart FailureHeart Decompensation

Interventions

DRUG

Cinaciguat (BAY58-2667)

Infusion of 150 µg/h during 48h.

DRUG

Cinaciguat (BAY58-2667)

Infusion of 100 µg/h during 48h

DRUG

Cinaciguat (BAY58-2667)

Infusion of 50 µg/h during 48h

DRUG

Placebo

Infusion during 48h

Trial Locations (70)

8

Dublin

1027

Budapest

1096

Budapest

1449

Johannesburg

2194

Johannesburg

6000

Kecskemét

6850

Worcester

7580

Kuils River

8000

Székesfehérvár

10034

Prague

12200

Berlin

13100

Safed

15006

Prague

15030

Prague

16164

Pontedecimo

24105

Kiel

28222

Majadahonda

30120

El Palmar

31096

Haifa

34212

Melsungen

35128

Padua

41063

Mönchengladbach

44100

Ferrara

44195

Cleveland

45267

Cincinnati

48010

Cotignola

48201

Detroit

54201

Dommartin-lès-Toul

60610

Chicago

70124

Bari

73042

Casarano

75013

Paris

75181

Paris

75475

Paris

76100

Rehovot

77030

Houston

86021

Poitiers

90471

Nuremberg

99089

Erfurt

37232-7240

Nashville

T2N 4Z6

Calgary

V5Z 1M9

Vancouver

G1V 4G5

Québec

625 00

Brno

532 03

Pardubice

Unknown

Jyväskylä

Turku

Ballinasloe

Nahariya

H-1096

Budapest

DUBLIN 4

Dublin

00161

Roma

00192

Roma

920-8650

Kanazawa

892-0853

Kagoshima

253-8558

Chigasaki

399-8701

Matsumoto

421-0193

Shizuoka

411-8611

Sunto

646-8558

Tanabe

85-681

Bydgoszcz

31-121

Krakow

10-228

Olsztyn

70-965

Szczecin

110-744

Seoul

138-736

Seoul

03186

Torrevieja

08035

Barcelona

HA1 3UJ

Harrow

NN1 5BD

Northampton